Thermo Fisher Scientific announces 510(k) clearance of molecular clinical test for SARS-CoV-2, Flu A, Flu B, and RSV
Feb. 10, 2025
Thermo Fisher Scientific has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B, RSV Select Panel.
This real-time PCR-based multiplex test covers the detection and differentiation of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) and enables detection of co-infection.
The TaqPath COVID-19, Flu A, Flu B, RSV Select Panel enables detection and differentiation of common respiratory viruses in one patient sample. This helps clinicians get fast, accurate results in as little as three hours that enable them to make informed decisions on patient treatment.
